(Q34144546)

31 July 2017

1 reference

title

Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment (English)

1 reference

31 July 2017

Ensaculin (KA-672. HCl): A Multitransmitter Approach to Dementia Treatment (English)

0 references

1 reference

Robert Hoerr

1

1 reference

31 July 2017

Michael Noeldner

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2002

1 reference

CNS Neuroscience & Therapeutics

31 July 2017

7 June 2006

0 references

published in

1 reference

31 July 2017

volume

8

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

143-158

1 reference

KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo.

31 July 2017

cites work

1 reference

12 December 2020

Acute effect of KA-672, a putative cognitive enhancer, on neurotransmitter receptor binding in mouse brain.

1 reference

12 December 2020

Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate

1 reference

12 December 2020

In vivo effects of the putative cognitive enhancer KA-672.HCl in comparison with 8-hydroxy-2-(di-N-propylamino) tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cor

1 reference

12 December 2020

Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.

1 reference

12 December 2020

Behavioral and electrophysiological effects of peptides related to lipotropin (beta-LPH)

1 reference

12 December 2020

Anticonvulsant drug toxicity in rat brain cell aggregate cultures.

1 reference

12 December 2020

Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type

1 reference

12 December 2020

NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease

1 reference

12 December 2020

Inhibitory effect of ACTH and related peptides on extinction of conditioned avoidance behavior in rats.

1 reference

12 December 2020

Growth and differentiation of aggregating fetal brain cells in a serum-free defined medium

1 reference

12 December 2020

Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability

1 reference

12 December 2020

An aggregate brain cell culture model for studying neuronal degeneration and regeneration.

1 reference

12 December 2020

The neurotrophic effects of ebiratide, an analog of ACTH4-9, on cultured septal cells and aged rats

1 reference

12 December 2020

Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease.

1 reference

12 December 2020

Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM.

1 reference

12 December 2020

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

1 reference

12 December 2020

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

1 reference

12 December 2020

KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers

1 reference

12 December 2020

Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?

1 reference

12 December 2020

The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component

1 reference

12 December 2020

The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist

1 reference

12 December 2020

10.1111/J.1527-3458.2002.TB00220.X

Identifiers

DOI

0 references

PMC publication ID

6741668

0 references

1 reference